Literature DB >> 12519538

Prophylactic antibiotics for inhibiting preterm labour with intact membranes.

J King1, V Flenady.   

Abstract

BACKGROUND: The contribution of subclinical genital tract infection to the aetiology of preterm birth is gaining increasing recognition, but the role of prophylactic antibiotic treatment in the management of preterm labour is uncertain. Since rupture of the membranes is an important factor in the progression of preterm labour, it is important to see if the routine administration of antibiotics confers any benefit, prior to membrane rupture.
OBJECTIVES: To assess the effects of prophylactic antibiotics administered to women in preterm labour with intact membranes, on maternal and neonatal outcomes. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's specialised register of controlled trials (May 2002), the Cochrane Controlled Trials Register (The Cochrane Library, Issue 1, 2002), MEDLINE (1965 to May 2002). Other sources included contacting recognised experts and cross referencing relevant material. SELECTION CRITERIA: Randomised trials which compared antibiotic treatment with placebo or no treatment for women in preterm labour (between 20 and 36 weeks' gestation) with intact membranes. DATA COLLECTION AND ANALYSIS: Standard methods of the Cochrane Collaboration and the Cochrane Pregnancy and Childbirth Group were used. Evaluation of methodological quality and trial data extraction were undertaken independently by the authors. Results are presented using relative risk for categorical data and weighted mean difference for continuous data. MAIN
RESULTS: This review has been updated (2002) to include data from the 'ORACLE II 2001' trial (six times larger than the previous 10 trials combined), which now dominates the results of this review. Meta-analysis of the 11 included trials (7428 women enrolled) shows a reduction in maternal infection with the use of prophylactic antibiotics (relative risk 0.74, 95% confidence interval 0.64 to 0.87) but fails to demonstrate a benefit or harm for any of the prespecified neonatal outcomes. REVIEWER'S
CONCLUSIONS: This review fails to demonstrate a clear overall benefit from prophylactic antibiotic treatment for preterm labour with intact membranes on neonatal outcomes and raises concerns about increased neonatal mortality for those who received antibiotics. This treatment cannot therefore be currently recommended for routine practice. Further research may be justified (when sensitive markers for subclinical infection become available) in order to determine if there is a subgroup of women who could experience benefit from antibiotic treatment for preterm labour prior to membrane rupture, and to identify which antibiotic or combination of antibiotics is most effective.

Entities:  

Mesh:

Year:  2002        PMID: 12519538     DOI: 10.1002/14651858.CD000246

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  35 in total

Review 1.  Obstetric issues in preterm birth.

Authors:  Deirdre J Murphy; Peter W Fowlie; William McGuire
Journal:  BMJ       Date:  2004-10-02

2.  Practices for predicting and preventing preterm birth in Ireland: a national survey.

Authors:  V Smith; D Devane; S Higgins
Journal:  Ir J Med Sci       Date:  2010-10-17       Impact factor: 1.568

Review 3.  Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality.

Authors:  Lars G Hemkens; Despina G Contopoulos-Ioannidis; John P A Ioannidis
Journal:  CMAJ       Date:  2013-10-21       Impact factor: 8.262

4.  Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) - Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes.

Authors:  Richard Berger; Harald Abele; Franz Bahlmann; Ivonne Bedei; Klaus Doubek; Ursula Felderhoff-Müser; Herbert Fluhr; Yves Garnier; Susanne Grylka-Baeschlin; Hanns Helmer; Egbert Herting; Markus Hoopmann; Irene Hösli; Udo Hoyme; Alexandra Jendreizeck; Harald Krentel; Ruben Kuon; Wolf Lütje; Silke Mader; Holger Maul; Werner Mendling; Barbara Mitschdörfer; Tatjana Nicin; Monika Nothacker; Dirk Olbertz; Werner Rath; Claudia Roll; Dietmar Schlembach; Ekkehard Schleußner; Florian Schütz; Vanadin Seifert-Klauss; Susanne Steppat; Daniel Surbek
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-08-12       Impact factor: 2.915

5.  Transplacental transfer of Azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model.

Authors:  Edward P Acosta; Peta L Grigsby; Kajal B Larson; Amanda M James; Mary C Long; Lynn B Duffy; Ken B Waites; Miles J Novy
Journal:  J Infect Dis       Date:  2013-10-31       Impact factor: 5.226

Review 6.  Antibiotics for ureaplasma in the vagina in pregnancy.

Authors:  Camille H Raynes Greenow; Christine L Roberts; Jane C Bell; Brian Peat; Gwendolyn L Gilbert; Sharon Parker
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

7.  Antibiotic Therapy for Premature Rupture of Membranes and Preterm Labor and Effect on Fetal Outcome.

Authors:  B Seelbach-Goebel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

8.  Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model.

Authors:  Michael G Gravett; Kristina M Adams; Drew W Sadowsky; Alexandra R Grosvenor; Steven S Witkin; Michael K Axthelm; Miles J Novy
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

Review 9.  Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.

Authors:  Fernando C Barros; Zulfiqar Ahmed Bhutta; Maneesh Batra; Thomas N Hansen; Cesar G Victora; Craig E Rubens
Journal:  BMC Pregnancy Childbirth       Date:  2010-02-23       Impact factor: 3.007

10.  Critical appraisal and clinical utility of atosiban in the management of preterm labor.

Authors:  Olaleye Sanu; Ronald F Lamont
Journal:  Ther Clin Risk Manag       Date:  2010-04-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.